Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
SEP-479 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Single Ascending Dose | EXPERIMENTAL | - |
| Multiple Ascending Dose | EXPERIMENTAL | - |
| Food Effect | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| SEP-479 | DRUG | Oral, capsule |
| Placebo | OTHER | Oral, capsule |
Inclusion Criteria: 1. Subjects who are able and willing to provide informed consent 2. Aged 21 to 60 years at the time of consent 3. Have a BMI within the range 18.0 to 32.0 kg/m2 4. In general good health Exclusion Criteria: 1. Any condition, which in the investigator's opinion might jeopardize...
SEP-479 is an investigational small molecule being studied in healthy volunteers. It is currently in Phase 1 clinical development, with a trial evaluating single and multiple doses in healthy adult participants. The drug is not yet approved and is still in clinical testing.
SEP-479 targets the parathyroid hormone 1 receptor (PTH1R), which is a G protein-coupled receptor (GPCR). By targeting this receptor, the drug is designed to modulate its activity, though the specific therapeutic application is still under investigation in early-stage trials.
SEP-479 is being developed by Septerna, Inc., a biopharmaceutical company. The company is conducting a Phase 1 clinical trial of SEP-479 in healthy volunteers, with the study currently recruiting participants in Australia.
SEP-479 is in Phase 1 clinical development. The ongoing trial, NCT07433179, is a randomized, double-blind, controlled study evaluating single and multiple doses of SEP-479 in healthy adult participants. The drug is investigational and has not been approved by regulatory authorities.
SEP-479 is being studied in one active Phase 1 clinical trial, NCT07433179, titled 'A Study to Evaluate Single and Multiple Doses of SEP-479 in Healthy Adult Participants.' This trial is recruiting 150 healthy adults aged 21 years and older in Australia and is randomized, double-blind, and controlled.